Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Axsome Therapeutics, Inc. - Common Stock
(NQ:
AXSM
)
105.07
+0.72 (+0.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 23, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Axsome Therapeutics, Inc. - Common Stock
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
21
22
Next >
Axsome Therapeutics Voices its Commitment to Mental Health on World Mental Health Day 2022
October 10, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
These 7 Biotech Stocks Are Set to Boom in 2023
October 10, 2022
This article looks at seven biotech stocks that look like good options to move significantly higher in 2023
Via
InvestorPlace
Better Buy: Moderna vs. Axsome Therapeutics
October 10, 2022
Both of these biotechs offer exciting future prospects.
Via
The Motley Fool
If You Invested $5,000 in Axsome Therapeutics in 2019, This Is How Much You Would Have Today
October 08, 2022
Could the stock keep performing?
Via
The Motley Fool
Jim Cramer On This Industrial Stock: 'You Don't Know What's In It'
October 07, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying Sociedad Quimica y Minera de Chile (NYSE: SQM) as "fertilizer’s in short supply and so is lithium."
Via
Benzinga
Axsome Therapeutics' Sunosi Improves Cognitive Function In Patients With Sleep Disorder
October 03, 2022
Via
Benzinga
8 Analysts Have This to Say About Axsome Therapeutics
September 30, 2022
Analysts have provided the following ratings for Axsome Therapeutics (NASDAQ:AXSM) within the last quarter:
Via
Benzinga
Mizuho Bolsters Price Target By 55% On This Migraine Stock
September 07, 2022
Via
Benzinga
3 Stocks Savvy Investors Are Buying Hand Over Fist
October 06, 2022
These high-flying stocks are defying the bear market.
Via
The Motley Fool
Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea
October 03, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
September 29, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting
September 29, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Analyst Ratings for Axsome Therapeutics
August 30, 2022
Within the last quarter, Axsome Therapeutics (NASDAQ:AXSM) has observed the following analyst ratings:
Via
Benzinga
Expert Ratings for Axsome Therapeutics
August 30, 2022
Within the last quarter, Axsome Therapeutics (NASDAQ:AXSM) has observed the following analyst ratings:
Via
Benzinga
These Were the Five Best And Worst Performing Mid-Cap Stocks In August 2022
September 20, 2022
We have used the August return data from finviz.com to come up with the five best and worst performing mid-cap stocks in August 2022.
Via
Talk Markets
7 Top-Rated Biotech Stocks to Buy for Q4
September 15, 2022
A new White House program makes these seven names some outstanding biotech stocks to buy for the fourth quarter.
Via
InvestorPlace
Biotech Stocks Stand to Benefit as Biden Announces Support for Industry
September 12, 2022
President Biden has announced a new initiative to help U.S. biotech producers grow. Here's what this news means for biotech stocks.
Via
InvestorPlace
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary
September 08, 2022
Via
Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
September 01, 2022
Via
Benzinga
Boxed Warnings May Not Hinder This Depression Drug's Broad Market Penetration, Analyst Says
August 23, 2022
Via
Benzinga
Axsome Therapeutics Commences Late-Stage Migraine Study
September 01, 2022
Axsome Therapeutics (NASDAQ: AXSM) has enrolled the first patient in the EMERGE trial of its lead candidate AXS-07 for the acute treatment of migraine.
Via
Benzinga
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
August 31, 2022
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.
Via
Benzinga
HC Wainwright Boosts Price Target On This Stock By 167%, Plus B of A Securities Predicts $40 For This Online Travel Stock
August 30, 2022
HC Wainwright & Co. raised the price target for Rockwell Medical, Inc. (NASDAQ: RMTI) from $3 to $8. Rockwell Medical shares rose 0.7% to close at $1.42 on Monday.
Via
Benzinga
$1000 Invested In Axsome Therapeutics 5 Years Ago Would Be Worth This Much Today
August 29, 2022
Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 5 years by 57.38% on an annualized basis producing an average annual return of 67.54%. Currently, Axsome Therapeutics has a...
Via
Benzinga
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others
August 29, 2022
These names are benefitting from M&A, clinical data and promising regulatory actions.
Via
Investor's Business Daily
AXSOME THERAPEUTICS INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Axsome Therapeutics, Inc. - AXSM
August 26, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
AMC Entertainment Price Target Cut By This Analyst, Plus DA Davidson Predicts $318 For Estée Lauder
August 23, 2022
DA Davidson cut the price target for The Estée Lauder Companies Inc. (NYSE: EL) from $342 to $318. Estée Lauder shares fell 0.4% to $264.29 in pre-market trading.
Via
Benzinga
Netflix Price Target Cut By This Analyst, Plus Morgan Stanley Predicts $403 For McKesson
August 22, 2022
UBS cut the price target for Coupa Software Incorporated (NASDAQ: COUP) from $84 to $76. Coupa Software shares fell 4.9% to $64.44 in pre-market trading.
Via
Benzinga
Why GigaCloud Technology Jumped 206%; Here Are 79 Biggest Movers From Yesterday
August 22, 2022
Gainers GigaCloud Technology Inc (NASDAQ: GCT) shares jumped 206% to close at $48.01 on Friday on continued volatility following the company's IPO on Thursday.
Via
Benzinga
Stocks That Made New Highs On Friday, Aug. 19
August 21, 2022
On Friday, in spite of the stock market being down, there were several stocks that actually made new highs.
Via
Talk Markets
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
21
22
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.